Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06632353
Active, not recruiting Observational

Biomarkers in Dermal Interstitial Fluid for Early Diagnosis and Follow-up of Cardiovascular Diseases

NCT06632353 · tracked via the Priya Life Science Sweden tracker
Sponsor
Ascilion AB
Phase
Observational
Started
2024-10-08
Last updated
2026-01-26

Condition(s) studied

Cardiovascular Diseases

Study summary

Sampling of dISF and blood plasma for qualitative measurements.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: Group 1: Chronic heart failure with stable therapy. NYHA classification II, III and IV. Age \> 60 years. Group 2: Age 18-40 years. Exclusion criteria: * Participating in another clinical investigation which may affect the study outcome according to clinical judgement. * Previous use of sampling system used. * Pregnancy or lactating. * Any disease or condition that may be affected. * Individuals who lack the ability to fully consent to participate in the study. * Severe skin injury. * Tattoo or piercing close to sampling area. * Group 1: All forms of emergency care. * Group 1: Non-stable therapy. * Group 1: Sepsis. * Group 1: BMI \> 30kg/m2. * Group 1: Age \> 84 years. * Group 2: Known heart or vascular disease. * Group 2: Diabetes. * Group 2: Kidney disease.

Primary outcome measure(s)

  • Presence of dISF biomarker — Day 1
    Presence or not

Trial sites (1)

FacilityCityRegionStatus
Danderyd Hospital Danderyd Sweden

Other trials for the same condition

The Causal Effect of Bariatric Surgery on Cardiovascular Disease and Mortality Recruiting
Prospective Urban Rural Epidemiology Study Recruiting
Evaluation of Cascade Screening for Elevated Lipoprotein(a) Active, not recruiting
An Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study Enrolling by invitation
A Digital Lifestyle Intervention in Primary Healthcare to Prevent Cardiovascular Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06632353 on ClinicalTrials.gov ↗ ← All trials in Sweden